Aprea Therapeutics(APRE.US)

Last Updated 19:00:00 ET
longbridge loading

Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target

Tip Ranks·
US
APRE
-5.35%
US
SBIO
-1.24%
US
LABD
+2.41%
Tip Ranks·
US
APRE
-5.35%
US
SBIO
-1.24%
US
LABD
+2.41%

Key facts: APRE APR‑1051, ATRN‑119 progress; Q1 loss $0.22

TradingView·
US
APRE
-5.35%
US
PBE
+0.11%
US
FBT
+0.54%
TradingView·
US
APRE
-5.35%
US
PBE
+0.11%
US
FBT
+0.54%

Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary

TradingView·
US
APRE
-5.35%
US
XBI
-0.69%
US
PBE
+0.11%
TradingView·
US
APRE
-5.35%
US
XBI
-0.69%
US
PBE
+0.11%

Aprea Therapeutics | 8-K: FY2026 Q1 Revenue Meets Estimate at USD 0

Earnings Watch·
US
APRE
-5.35%
Earnings Watch·
US
APRE
-5.35%

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Unusual Whales·
US
APRE
-5.35%
US
SBIO
-1.24%
US
FBT
+0.54%
Unusual Whales·
US
APRE
-5.35%
US
SBIO
-1.24%
US
FBT
+0.54%

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

benzinga_article·
US
CNH
-2.57%
US
APRE
-5.35%
US
SRFM
-3.48%
benzinga_article·
US
CNH
-2.57%
US
APRE
-5.35%
US
SRFM
-3.48%

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga_article·
US
CNSP
+1.49%
US
CELC
-0.92%
US
APRE
-5.35%
benzinga_article·
US
CNSP
+1.49%
US
CELC
-0.92%
US
APRE
-5.35%
© 2026 Longbridge｜Disclaimer